Signos is the first FDA-cleared metabolic health platform that helps employees understand and improve their metabolism in real-time, providing employers with the data to make informed benefits decisions.Powered by Dexcom’s Stelo CGM and AI-driven guidance, Signos turns glucose data into personalized, actionable recommendations that support sustainable weight management and better metabolic health. For employers, this means healthier populations, reduced reliance on GLP-1 medications, and more predictable benefit costs through data-driven, predictive health.